{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:41:09Z","timestamp":1708515669949},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1007\/bf03402030","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T08:45:54Z","timestamp":1536223554000},"page":"667-675","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular Evidence-Based Use of Bone Resorption-Targeted Therapy in Prostate Cancer Patients at High Risk for Bone Involvement"],"prefix":"10.1007","volume":"8","author":[{"given":"Dimitrios","family":"Karamanolakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antigone","family":"Sourla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine","family":"Milathianakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanassios","family":"Tsintavis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lembessis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxane","family":"Tenta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Tiblalexi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Koutsilieris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,11,1]]},"reference":[{"key":"BF03402030_CR1","first-page":"1159","volume-title":"Campbells Urology","author":"TA Stamey","year":"1992","unstructured":"Stamey TA, McNeal JE. (1992) Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, et al. (eds). Campbells Urology, volume 1. Philadelphia: Saunders; pp.1159\u20131221."},{"key":"BF03402030_CR2","first-page":"89","volume":"9","author":"M Koutsilieris","year":"1996","unstructured":"Koutsilieris M, Dimopoulos MA, Doillon C, Sourla A, Reyes-Moreno C, Choki I. (1996) The molecular concept of prostate cancer. Cancer J. 9: 89\u201394.","journal-title":"Cancer J."},{"key":"BF03402030_CR3","first-page":"443","volume":"13","author":"M Koutsilieris","year":"1993","unstructured":"Koutsilieris M. (1993) Osteoblastic metastases in advanced prostate cancer. Anticancer Res. 13: 443\u2013449.","journal-title":"Anticancer Res."},{"key":"BF03402030_CR4","first-page":"333","volume":"10","author":"M Koutsilieris","year":"1990","unstructured":"Koutsilieris M, Laroche B, Thabet M, Fradet Y. (1990) The assessment of disease aggressivity in stage D2 prostate cancer patients. Anticancer Res. 10: 333\u2013336.","journal-title":"Anticancer Res."},{"key":"BF03402030_CR5","first-page":"18","volume":"19","author":"TA Guise","year":"1998","unstructured":"Guise TA, Mundy GR (1998) Cancer and bone. Endocr. Rev. 19: 18\u201354.","journal-title":"Endocr. Rev."},{"key":"BF03402030_CR6","first-page":"20","volume":"12","author":"CS Galasko","year":"1982","unstructured":"Galasko CS. (1982) Mechanism of lytic and blastic metastatic disease of bone. Clin. Orthop. 12: 20\u201327.","journal-title":"Clin. Orthop."},{"key":"BF03402030_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","volume":"80","author":"GR Mundy","year":"1997","unstructured":"Mundy GR. (1997) Mechanisms of bone metastasis. Cancer 80: 1546\u20131556.","journal-title":"Cancer"},{"key":"BF03402030_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0090-4295(86)90278-5","volume":"27","author":"M Koutsilieris","year":"1986","unstructured":"Koutsilieris M, Faure N, Tolis G, et al. (1986) Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with disease response and outcome. Urology 27: 221\u2013228.","journal-title":"Urology"},{"key":"BF03402030_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/BF03401935","volume":"6","author":"M Koutsilieris","year":"2000","unstructured":"Koutsilieris M, Mitsiades C, Sourla A. (2000) Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Mol. Med. 6: 251\u2013267.","journal-title":"Mol. Med."},{"key":"BF03402030_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1517\/13543784.10.6.1099","volume":"10","author":"CS Mitsiades","year":"2001","unstructured":"Mitsiades CS, Koutsilieris M. (2001) Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin. Investig. Drug 10: 1099\u20131115.","journal-title":"Expert Opin. Investig. Drug"},{"key":"BF03402030_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/1040-8428(94)00122-A","volume":"18","author":"M Koutsilieris","year":"1995","unstructured":"Koutsilieris M. (1995) Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit. Rev. Oncol. Hematol. 18: 51\u201364.","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"BF03402030_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJM198908173210702","volume":"17","author":"ED Crawford","year":"1989","unstructured":"Crawford ED, Eisenberger MA, McLeod DG, et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med 17: 419\u2013424.","journal-title":"N. Engl. J. Med"},{"key":"BF03402030_CR13","first-page":"1517","volume":"17","author":"P Behrakis","year":"1997","unstructured":"Behrakis P, Koutsilieris M. (1997) Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy. Anticancer Res. 17: 1517\u20131518.","journal-title":"Anticancer Res."},{"key":"BF03402030_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/pros.2990040606","volume":"4","author":"G Tolis","year":"1983","unstructured":"Tolis G, Koutsilieris M, Fazekas AT, Patton R. (1983) Transabdominal ultrasonography in the evaluation of patients with advanced prostatic carcinoma: effects of castration and of chronic administration of a gonadotrophin releasing hormone agonistic analogue. Prostate 4: 595\u2013600.","journal-title":"Prostate"},{"key":"BF03402030_CR15","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","volume":"140","author":"RJ Thomas","year":"1993","unstructured":"Thomas RJ, Guise TA, Yin JJ, et al. (1993) Breast cancer cells interact with osteoclasts to support osteoclast formation. Endocrinology 140: 4451\u20134458.","journal-title":"Endocrinology"},{"key":"BF03402030_CR16","first-page":"481","volume":"13","author":"M Koutsilieris","year":"1993","unstructured":"Koutsilieris M, Frenette G, Lazure C, et al. (1993) Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res. 13: 481\u2013486.","journal-title":"Anticancer Res."},{"key":"BF03402030_CR17","doi-asserted-by":"publisher","first-page":"S1581","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1581::AID-CNCR8>3.0.CO;2-N","volume":"80","author":"D Goltzman","year":"1997","unstructured":"Goltzman D. (1997) Mechanisms of the development of osteoblastic metastases. Cancer 80: S1581\u2013S1587.","journal-title":"Cancer"},{"key":"BF03402030_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/bjc.1998.658","volume":"78","author":"P Autzen","year":"1998","unstructured":"Autzen P, Robson CN, Bjartell A, et al (1998) Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer 78: 1219\u20131223.","journal-title":"Br. J. Cancer"},{"key":"BF03402030_CR19","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nm0995-944","volume":"1","author":"JB Nelson","year":"1995","unstructured":"Nelson JB, Hedican SP, George DJ, et al. (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1: 944\u2013949.","journal-title":"Nat. Med."},{"key":"BF03402030_CR20","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0090-4295(98)00658-X","volume":"53","author":"JB Nelson","year":"1999","unstructured":"Nelson JB, Nguyen SH, Wu-Wong JR, et al. (1999) New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53: 1063\u20131069.","journal-title":"Urology"},{"key":"BF03402030_CR21","first-page":"2602","volume":"61","author":"MV Lee","year":"2001","unstructured":"Lee MV, Fong EM, Singer FR, Guenette RS. (2001) Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61: 2602\u20132608.","journal-title":"Cancer Res."},{"key":"BF03402030_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0090-4295(98)00182-4","volume":"52","author":"C Reyes-Moreno","year":"1998","unstructured":"Reyes-Moreno C, Sourla A, Choki I, et al. (1998) Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology 52: 341\u2013347.","journal-title":"Urology"},{"key":"BF03402030_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1517\/13543784.11.2.283","volume":"11","author":"M Koutsilieris","year":"2002","unstructured":"Koutsilieris M, Mitsiades C, Dimopoulos T, et al. (2002) Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer. Expert Opin. Investig. Drugs 11: 283\u2013293.","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BF03402030_CR24","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1210\/jcem.86.12.8119","volume":"86","author":"M Koutsilieris","year":"2001","unstructured":"Koutsilieris M, Mitsiades C, Dimopoulos T, et al. (2001) A combination of dexamethasone and a somatostatin analogue reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J. Clin. Endocrinol. Metab. 86: 5729\u20135736.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03402030_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0022-5347(01)64472-0","volume":"158","author":"LG Gomella","year":"1997","unstructured":"Gomella LG, Raj GV, Moreno JG. (1997) Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J. Urol. 158: 326\u2013337.","journal-title":"J. Urol."},{"key":"BF03402030_CR26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/bjc.1997.114","volume":"75","author":"T Deguchi","year":"1997","unstructured":"Deguchi T, Yang M, Ehara H, et al. (1997) Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br. J. Cancer 75: 634\u2013638.","journal-title":"Br. J. Cancer"},{"key":"BF03402030_CR27","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0022-5347(01)67407-X","volume":"153","author":"C Cama","year":"1995","unstructured":"Cama C, Olsson CA, Raffo AJ, et al. (1995) Molecular staging of prostate cancer. II. A comparison of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J. Urol. 153: 1373\u20131378.","journal-title":"J. Urol."},{"key":"BF03402030_CR28","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","volume":"12","author":"JC Frith","year":"1997","unstructured":"Frith JC, Monkkonen J, Blackburn GM, et al. (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-b,g-dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 12: 1358\u20131367.","journal-title":"J. Bone Miner. Res."},{"key":"BF03402030_CR29","first-page":"56","volume":"14","author":"RGG Russell","year":"1999","unstructured":"Russell RGG, Rogers MJ, Frith JC, et al. (1999) The pharmacology of bisphosphonates and new insights into their mechanism of action. J. Bone Miner. Res. 14: 56\u201365.","journal-title":"J. Bone Miner. Res."},{"key":"BF03402030_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP, Hughes DE, Coxon FP, et al. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-transnational prenylation of GTP-binding proteins including Ras. J. Bone Miner. Res. 13: 581\u2013589.","journal-title":"J. Bone Miner. Res."},{"key":"BF03402030_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1359\/jbmr.1999.14.5.722","volume":"14","author":"E Van Beek","year":"1999","unstructured":"Van Beek E, Lowik C, van der Pluijm G, Papadopoulos S. (1999) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of nitrogen-containing bisphosphonates. J. Bone Miner. Res. 14: 722\u2013729.","journal-title":"J. Bone Miner. Res."},{"key":"BF03402030_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S8756-3282(01)00592-0","volume":"29","author":"L Alvarez","year":"2001","unstructured":"Alvarez L, Guanabens N, Peris P, et al. (2001) Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget\u2019s disease. Bone 29: 447\u2013452.","journal-title":"Bone"},{"key":"BF03402030_CR33","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/S0024-3205(01)01548-X","volume":"70","author":"MB Zimering","year":"2002","unstructured":"Zimering MB. (2002) Effect of intravenous bisphosphonates on release of basic fibroblast growth factor in serum of patients with cancer-associated hypercalcemia. Life Sci. 70: 1947\u20131960.","journal-title":"Life Sci."},{"key":"BF03402030_CR34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/1097-0142(19830301)51:5<918::AID-CNCR2820510526>3.0.CO;2-J","volume":"51","author":"SA Charhon","year":"1983","unstructured":"Charhon SA, Chapuy MC, Delvin EE, et al. (1983) Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer 51: 918\u2013924.","journal-title":"Cancer"},{"key":"BF03402030_CR35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1464-410X.1985.tb07040.x","volume":"57","author":"GH Urwin","year":"1985","unstructured":"Urwin GH, Percival RC, Harris S, et al. (1985) Generalized increase in bone resorption in carcinoma of the prostate. Eur. J. Urol. 57: 721\u2013723.","journal-title":"Eur. J. Urol."},{"key":"BF03402030_CR36","first-page":"41","volume":"13","author":"RC Percival","year":"1987","unstructured":"Percival RC, Urwin GH, Harris S, et al. (1987) Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur. J. Surg. Oncol. 13: 41\u201349.","journal-title":"Eur. J. Surg. Oncol."},{"key":"BF03402030_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","volume":"68","author":"NW Clarke","year":"1991","unstructured":"Clarke NW, McClure J, George NJR. (1991) Morphometric evidence for bone resorption and replacement in prostate cancer. Br. J. Urol. 68: 74\u201380.","journal-title":"Br. J. Urol."},{"key":"BF03402030_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/0959-8049(94)90287-9","volume":"30","author":"T Taube","year":"1994","unstructured":"Taube T, Kylmala T, Lamberg-Allardt C, Tammela TL, Elomaa I. (1994) The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double blind randomized placebo-controlled study. Eur. J. Cancer. 30: 751\u2013758.","journal-title":"Eur. J. Cancer"},{"key":"BF03402030_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1046\/j.1464-410X.1996.82817.x","volume":"77","author":"I Ikeda","year":"1996","unstructured":"Ikeda I, Miura T, Kondo I. (1996) Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br. J. Urol. 77: 102\u2013106.","journal-title":"Br. J. Urol."},{"key":"BF03402030_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0022-5347(01)65196-6","volume":"157","author":"H Maeda","year":"1997","unstructured":"Maeda H, Koizumi M, Yoshimura K, et al. (1997) Correlation between bone metabolic markers and bone scan in prostatic cancer. J. Urol. 157: 539\u2013543.","journal-title":"J. Urol."},{"key":"BF03402030_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","volume":"20","author":"T Suda","year":"1999","unstructured":"Suda T, Takahashi N, Udagawa N, et al. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20: 345\u2013357.","journal-title":"Endocr. Rev."},{"key":"BF03402030_CR42","first-page":"2949","volume":"60","author":"S Boissier","year":"2000","unstructured":"Boissier S, Ferreras M, Peyruchaud O. (2000) Bisphosphonates inhibits breast and prostate carcinoma cell invasion, an early event in the formation of bone metastasis. Cancer Res. 60: 2949\u20132954.","journal-title":"Cancer Res."},{"key":"BF03402030_CR43","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/NEJM199808063390609","volume":"339","author":"GR Mundy","year":"1998","unstructured":"Mundy GR, Yoneda T. (1998) Bisphosphonates as anticancer drugs. N. Engl. J. Med. 339: 398\u2013400.","journal-title":"N. Engl. J. Med."},{"key":"BF03402030_CR44","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1002\/1097-0142(20000615)88:12+<3047::AID-CNCR22>3.0.CO;2-U","volume":"88","author":"SE Papadopoulos","year":"2000","unstructured":"Papadopoulos SE, Hamdy NAT, van der Pluijm G. (2000) Bisphosphonates in the management of prostatic carcinoma metastatic to the skeleton. Cancer 88: 3047\u20133053.","journal-title":"Cancer"},{"key":"BF03402030_CR45","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1200\/JCO.1998.16.3.1218","volume":"16","author":"DJ Bloomfield","year":"1998","unstructured":"Bloomfield DJ. (1998) Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence based review. J. Clin. Oncol. 16: 1218\u20131225.","journal-title":"J. Clin. Oncol."},{"key":"BF03402030_CR46","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"G Van der Pluijm","year":"1996","unstructured":"Van der Pluijm G, Vloedgraven H, van Beek E, et al. (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98: 698\u2013705.","journal-title":"J. Clin. Invest."},{"key":"BF03402030_CR47","first-page":"3890","volume":"57","author":"S Boissier","year":"1997","unstructured":"Boissier S, Magnetto S, Frappart L, et al. (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57: 3890\u20133894.","journal-title":"Cancer Res."},{"key":"BF03402030_CR48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1749-6632.1999.tb07702.x","volume":"878","author":"O Teronen","year":"1999","unstructured":"Teronen O, Heikkila P, Konttinen YT, et al. (1999) MMP inhibition and down regulation by bisphosphonates. Ann. N. Y. Acad. Sci. 878: 453\u2013465.","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BF03402030_CR49","unstructured":"Wood J, Schnell C, Green J. (2000) Zolendronic acid (ZOMETA) a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in human endothelial cells in vitro and is antiangiogenic in a murine growth factor implant model. Proc. Am. Soc. Clin. Oncol. 19: Abstract 2620."},{"key":"BF03402030_CR50","unstructured":"Miller PD. (2001) Bisphosphonates adjuvant therapy for prostate cancer. Proceedings of the 11th International Prostate Cancer Update, Colorado, January 31\u2013February 4, pp. 302\u2013304."},{"key":"BF03402030_CR51","doi-asserted-by":"crossref","unstructured":"Lipton A, Small I, Saad F, et al. (2002) The new bisphosphonate Zometa decreases skeletal complications in both lytic and blastic lesions. A comparison to pamidronate. Chemotherapy Foundation Symposium XIX: Innovative Cancer Therapy for Tomorrow.","DOI":"10.1081\/CNV-120014886"},{"key":"BF03402030_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0093-7754(01)90230-1","volume":"28","author":"RE Coleman","year":"2001","unstructured":"Coleman RE. (2001) Should bisphosphonates be the treatment of choice for metastatic bone disease? Semin. Oncol. 28: 35\u201341.","journal-title":"Semin. Oncol."},{"key":"BF03402030_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0090-4295(88)90410-4","volume":"32","author":"PO Carey","year":"1988","unstructured":"Carey PO, Lippert MC. (1988) Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology 32: 403\u2013407.","journal-title":"Urology"},{"key":"BF03402030_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","volume":"141","author":"JA Smith","year":"1989","unstructured":"Smith JA. (1989) Palliation of painful bone metastases from prostate cancer using sodium etidronate. Results of a randomized, prospective, double blind, placebo-controlled study. J. Urol. 141: 85\u201387.","journal-title":"J. Urol."},{"key":"BF03402030_CR55","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/S0022-5347(17)47663-4","volume":"134","author":"S Adami","year":"1985","unstructured":"Adami S, Salvagno G, Guarrera G, et al. (1985) Dichloromethylene diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J. Urol. 134: 1152\u20131154.","journal-title":"J. Urol."},{"key":"BF03402030_CR56","first-page":"67","volume":"116","author":"S Adami","year":"1989","unstructured":"Adami S, Mian M. (1989) Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results. Cancer Res. 116: 67\u201372.","journal-title":"Cancer Res."},{"key":"BF03402030_CR57","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1464-410X.1993.tb16269.x","volume":"72","author":"R Vorreuther","year":"1993","unstructured":"Vorreuther R. (1993) Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br. J. Urol. 72: 792\u2013795.","journal-title":"Br. J. Urol."},{"key":"BF03402030_CR58","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1464-410X.1995.tb07715.x","volume":"76","author":"SM Cresswell","year":"1995","unstructured":"Cresswell SM, English PJ, Hall RR, Roberts JT, Marsh MM. (1995) Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br. J. Urol. 76: 360\u2013365.","journal-title":"Br. J. Urol."},{"key":"BF03402030_CR59","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF02549644","volume":"24","author":"I Elomaa","year":"1992","unstructured":"Elomaa I, Kylmala T, Tammela T, et al. (1992) Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. Int. Urol. Nephrol. 24: 159\u2013166.","journal-title":"Int. Urol. Nephrol."},{"key":"BF03402030_CR60","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(89)92665-2","volume":"1","author":"T Masud","year":"1989","unstructured":"Masud T, Slevin ML. (1989) Pamidronate to reduce bone pain in normocaelcemic patient with disseminated prostatic carcinoma. Lancet 1: 1021\u20131022.","journal-title":"Lancet"},{"key":"BF03402030_CR61","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S0140-6736(89)93028-6","volume":"2","author":"RCM Pelger","year":"1989","unstructured":"Pelger RCM, Lyclama A, Nijeholt AAB, Papadopoulos SE. (1989) Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases. Lancet 2: 865.","journal-title":"Lancet"},{"key":"BF03402030_CR62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","volume":"68","author":"NW Clarke","year":"1991","unstructured":"Clarke NW, McClure J, George JR. (1991) Morphometric evidence for bone resorption and replacement in prostate cancer. Br. J. Urol. 68: 74\u201380.","journal-title":"Br. J. Urol."},{"key":"BF03402030_CR63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1464-410X.1992.tb15461.x","volume":"69","author":"NW Clarke","year":"1992","unstructured":"Clarke NW, McClure J, George NJR. (1992) Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br. J. Urol. 69: 64\u201370.","journal-title":"Br. J. Urol."},{"key":"BF03402030_CR64","first-page":"S31","volume":"5","author":"A Lipton","year":"1994","unstructured":"Lipton A, Clover D, Harvey H, et al. (1994) Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann. Oncol. 5: S31\u2013S35.","journal-title":"Ann. Oncol."},{"key":"BF03402030_CR65","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S8756-3282(97)00289-5","volume":"22","author":"RCM Pelger","year":"1998","unstructured":"Pelger RCM, Hamdy NAT, Zinderman AH, et al. (1998) Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 22: 403\u2013408.","journal-title":"Bone"},{"key":"BF03402030_CR66","first-page":"613","volume":"17","author":"D Raghavan","year":"1990","unstructured":"Raghavan D, Wallace M. (1990) Preemptive (neoadjuvant) chemotherapy: can analysis of eligibility criteria, prognostic factors, and tumor staging from different trials provide valid or useful comparisons? Semin. Oncol. 17: 613\u2013618.","journal-title":"Semin. Oncol."},{"key":"BF03402030_CR67","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1200\/JCO.1985.3.7.1013","volume":"3","author":"IF Tannock","year":"1992","unstructured":"Tannock IF. (1992) Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J. Clin. Oncol. 3: 1013\u20131021.","journal-title":"J. Clin. Oncol."},{"key":"BF03402030_CR68","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/1097-0142(197508)36:2<359::AID-CNCR2820360210>3.0.CO;2-1","volume":"36","author":"RE Belliveau","year":"1975","unstructured":"Belliveau RE, Spencer RP. (1975) Incidence and staging of bone lesions detected by 99mTc polyphosphate scans in patients with tumors. Cancer 36: 65\u201372.","journal-title":"Cancer"},{"key":"BF03402030_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/263507a0","volume":"263","author":"CS Galasko","year":"1976","unstructured":"Galasko CS. (1976) Mechanisms of bone destruction in the development of skeletal metastases. Nature 263: 507\u2013508.","journal-title":"Nature"},{"key":"BF03402030_CR70","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1002\/1097-0142(19950401)75:7<1642::AID-CNCR2820750714>3.0.CO;2-1","volume":"75","author":"AE Katz","year":"1995","unstructured":"Katz AE, de Vries GM, Begg MD, et al. (1995) Enhanced reverse transcriptase-polymerase chain reaction as an indicator of true pathologic stage in patients with prostate cancer. Cancer 75: 1642\u20131648.","journal-title":"Cancer"},{"key":"BF03402030_CR71","first-page":"1456","volume":"58","author":"YZ Grasso","year":"1998","unstructured":"Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA. (1998) Combined nested rt-PCR assay for prostate specific antigen and prostate specific membrane antigen in prostate cancer patients: correlation with pathologic stage. Cancer Res. 58: 1456\u20131459.","journal-title":"Cancer Res."},{"key":"BF03402030_CR72","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/clinchem\/41.12.1698","volume":"41","author":"S Loric","year":"1995","unstructured":"Loric S, Dumas F, Eschwege P, et al. (1995) Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse trancriptase polymerase chain reaction assay based on prostate specific membrane antigen. Clin. Chem. 41: 1698\u20131704.","journal-title":"Clin. Chem."},{"key":"BF03402030_CR73","first-page":"249","volume":"3","author":"SW Melchior","year":"1997","unstructured":"Melchior SW, Corey E, Ellis WJ, et al. (1997) Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin. Cancer Res. 3: 249\u2013256.","journal-title":"Clin. Cancer Res."},{"key":"BF03402030_CR74","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1464-410X.1996.90616.x","volume":"77","author":"CA Olsson","year":"1996","unstructured":"Olsson CA, de Vries MC, Benson MC, et al. (1996) The use of rt-PCR for prostate specific antigen assay to predict surgical failures before radical prostatectomy: molecular staging of the prostate cancer. Br. J. Urol. 77: 411\u2013417.","journal-title":"Br. J. Urol."},{"key":"BF03402030_CR75","first-page":"6306","volume":"54","author":"RS Israeli","year":"1994","unstructured":"Israeli RS, Miller WH Jr, Su SL, et al. (1994) Sensitive reverse transcriptase polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res. 54: 6306\u20136310.","journal-title":"Cancer Res."},{"key":"BF03402030_CR76","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0090-4295(96)00235-X","volume":"48","author":"AS Kibel","year":"1996","unstructured":"Kibel AS, Krithivas K, Shamel B, Kantoff PW, DeWolf WC. (1996) Constitutive expression of high levels of prostate antigen in the absence of prostate carcinoma. Urology 48: 741\u2013746.","journal-title":"Urology"},{"key":"BF03402030_CR77","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S0140-6736(95)92054-4","volume":"346","author":"P Eschwege","year":"1995","unstructured":"Eschwege P, Dumas F, Blancet P, et al. (1995) Heamatogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 346: 1528\u20131530.","journal-title":"Lancet"},{"key":"BF03402030_CR78","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1023\/A:1006783330996","volume":"17","author":"M Koutsilieris","year":"1999","unstructured":"Koutsilieris M, Lembessis P, Luu-The V, Sourla A. (1999) Repetitive and site-specific molecular staging of prostate cancer using reverse transcriptase polymerase chain reaction for PSA and PSMA. Clin. Exp. Metastases 17: 823\u2013830.","journal-title":"Clin. Exp. Metastases"},{"key":"BF03402030_CR79","first-page":"3665","volume":"21","author":"A Sourla","year":"2001","unstructured":"Sourla A, Lembessis P, Mitsiades C, et al. (2001) Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Res. 21: 3665\u20133570.","journal-title":"Anticancer Res."},{"key":"BF03402030_CR80","unstructured":"Lembessis P, Sourla A, Mitsiases C, Koutsilieris M. (2002) Significance of molecular staging in clinically localized and advanced stage prostate cancer. In Labrie F, Koutsilieris M (eds). Prostate Cancer: Understanding the Pathophysiology and Redesigning the Treatment. (in press)."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03402030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF03402030\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03402030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:11:38Z","timestamp":1708513898000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1007\/BF03402030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["BF03402030"],"URL":"https:\/\/doi.org\/10.1007\/bf03402030","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11]]},"assertion":[{"value":"23 September 2002","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2002","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}